We use cookies to improve your experience. By your continued use of this site you accept such use. To change your settings please see our Privacy Policy.
I accept

29 Mar. 2023

Focusing on Advanced Primary Ovarian Cancer Treatment, OEP Enters into an Exclusive License and Distribution Agreement of Oregovomab in Taiwan

 

Focusing on Advanced Primary Ovarian Cancer Treatment, OEP Enters into an Exclusive License and Distribution Agreement of Oregovomab in Taiwan_Commercial Times

Back
OEP

： +886-2-27554881

： oep@oepgroup.com

13F., No. 128, Sec. 6, Chengde Rd.,
Taipei 112, Taiwan, R.O.C.

Terms of Use | Privacy Policy

Copyright ©2024. Orient EuroPharma Co., Ltd. All rights reserved.